1. Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study. Issue 7 (July 2022) Authors: Knight, Stephen R; Shaw, Catherine A; Pius, Riinu; Drake, Thomas M; Norman, Lisa; Ademuyiwa, Adesoji O; Adisa, Adewale O; Aguilera, Maria Lorena; Al-Saqqa, Sara W; Al-Slaibi, Ibrahim; Bhangu, Aneel; Biccard, Bruce M; Brocklehurst, Peter; Costas-Chavarri, Ainhoa; Chu, Kathryn; Dare, Anna; Elhadi, ... Journal: Lancet Issue: Volume 10:Issue 7(2022) Page Start: e1003 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study. (4th October 2017) Authors: Kokai-Kun, John; Roberts, Tracey; Coughlin, Olivia; Whalen, Heidi; Le, Charles; Da Costa, Christopher; Sliman, Joseph Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Issue 5 (May 2019) Authors: Kokai-Kun, John F; Roberts, Tracey; Coughlin, Olivia; Le, Chenxiong; Whalen, Heidi; Stevenson, Ralph; Wacher, Vincent J; Sliman, Joseph Journal: Lancet infectious diseases Issue: Volume 19:Issue 5(2019) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗